National Institutes of Health (NIH) Consensus Criteria Describe the Clinical Features of Chronic Graft-Versus-Host Disease (cGVHD) in Children and Improve the Accuracy of cGVHD Diagnosis in a Multi-Institution Trial (ABLE / PBMTC 1202)
Geoff D.E. Cuvelier(CancerCare Manitoba), Kirk R. Schultz(University of British Columbia), Eneida R. Nemecek(Oregon Health & Science University), Anat Halevy(University of British Columbia), Tal Schechter(Hospital for Sick Children), Justin T. Wahlstrom(University of California, San Francisco), Victor Lewis(Alberta Children's Hospital), Carrie L. Kitko(Vanderbilt University Medical Center), David A. Jacobsohn(Children's National), S. Mcdonald(University of Mississippi Medical Center), Michael Boyer(Chris O’Brien Lifehouse), Donald W. Coulter(University of Nebraska Medical Center), Joseph H. Chewning(Kettering University), Joan Morris(Loma Linda University)
Cited by 1
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k